Survival rates for patients with Triple Negative Breast Cancer (TNBC) are as low as 11%. This type of breast cancer is more aggressive and with a poor prognosis since, at a very early stage, it develops metastases, i.e. secondary tumors in other organs. While patients with the most common hormone-dependent breast cancers find in the current chemotherapeutics a clinical cure, TNBC does not have any targeted treatment. As such these patients are subjected to a cocktail of drugs which increases their lives for a short time but do not treat them. In this frame, R-nuucell aims to address this unmet clinical need.
Our innovative ruthenium-based drug, protected by a granted international patent, has shown potential to treat TNBC metastases by targeting actin filaments which are long protein chains, a constituent of cell’s cytoskeleton (like cell’s foundation). Moreover, our drug is also able to overcome cancer multidrug resistance (MDR). Indeed, MDR is responsible for the treatments’ fail of more than 90% of metastatic cancers. Thus, our results are of primordial importance.
Within CanceRusolution we aim at consolidating the in vivo proof-of-concept by gathering data on our drug’s efficiency against TNBC metastases. Additionally, we will gather information on the drug pharmacokinetics by monitoring the concentration of the drug in the plasma, urine, tumor and organs.
The success of this project will be a key contribution to Science and Society. It will impact fundamental science by advancing the state of the art, and also encloses a real chance to develop a metallodrug suitable for an aggressive and untreatable type of cancer. We strongly believe we have a unique product that can save many lives given the opportunity.
